Sinedore Holdings Ltd (Sinedore) is proud to announce that it has been honored with the 22nd National Innovation Award (Startup Category). This recognition highlights the critical breakthrough of Sinedore’s core TransE™ platform in biologics delivery, showcasing the R&D excellence and global competitiveness of Taiwan’s biotech startups in the field of non-invasive macromolecule administration.
Transforming Injectable Biologics into Patient-Friendly Delivery
While biologics such as antibodies have become the gold standard for treating autoimmune and dermatological diseases, most still rely on injections. This often leads to patient discomfort, reduced compliance, and an increased burden on healthcare resources. Furthermore, the skin barrier remains a formidable natural obstacle for macromolecules, making transdermal antibody delivery one of the most challenging technical hurdles in the industry.
Sinedore’s TransE™ platform was engineered specifically to solve this industry pain point, aiming to deliver macromolecules to local or targeted sites in a safer, more convenient, and highly scalable manner.
Peptide Modulation: A Reversible, Precision “Key” for Safe Permeation
TransE™ utilizes a sophisticated Peptide Modulation mechanism to precisely regulate intercellular junctions. This technology allows the skin’s channels to open briefly for drug passage before returning to their original state, achieving safe, reversible, and highly efficient barrier penetration.
The technical team describes it with a metaphor: if the skin barrier is a locked city gate, TransE™ acts as a specialized “sensor key” that briefly opens the gate and allows it to close automatically once the medicine has passed. Unlike microneedles, TransE™ is positioned as a 100% non-invasive, painless, and scar-free solution with significant potential for low-cost, large-scale production.
Preclinical Evidence: Successful Transdermal Antibody Delivery in Psoriasis Models
Sinedore has established a quantifiable validation path using Psoriasis as a representative indication. Preclinical results demonstrate that TransE™-facilitated topical application successfully delivered IL-17 monoclonal antibodies (~150 kDa) to the dermis in mouse models. The study observed significant improvement in lesions, including a reduction in psoriasis-related epidermal hyperplasia, proving the scientific feasibility of the platform for local macromolecule delivery.
Commercial Validation: Global Licensing Strategy and Market Potential
The value of the TransE™ platform is already gaining significant international traction. Sinedore Holdings Ltd (Sinedore) has signed an exclusive licensing agreement with Lir Life Sciences, a publicly-traded international biotech firm, for the development of Transdermal Semaglutide in low- and middle-income countries.
This licensing deal is valued at up to NT$600 million (contingent upon contract terms and milestone achievements). Notably, Sinedore retains approximately 85% of global development and commercial rights, including major markets such as the U.S., Europe, and China. The company estimates the total commercial opportunity in these key markets to exceed NT$5 billion. Securing international licensing and revenue recognition at the preclinical stage reflects the market’s high expectations for Sinedore’s commercialization path.
Expanding Horizons: Autoimmune, Aesthetics, and Gene Therapy
Sinedore will continue to leverage the TransE™ modular platform to expand into autoimmune diseases, medical aesthetics, and other high-growth sectors. By pursuing a “scalable technology platform” strategy, Sinedore is committed to advancing more partnerships and product pipelines—ultimately providing a more precise, user-friendly, and needle-free generation of medical alternatives.
References:
